Frequently Asked Questions
The market is segmented based on , By Type (Familial, Acquired), Treatment (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
.
The Global Hyperlipidemia Market size was valued at USD 18.97 USD Billion in 2021.
The Global Hyperlipidemia Market is projected to grow at a CAGR of 2.9% during the forecast period of 2022 to 2029.
The major players operating in the market include F. HoffmannLa Roche , Mylan N.V., Teva Pharmaceutical Industries , Sanofi, Pfizer , GlaxoSmithKline plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries , Merck & Co., BristolMyers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals , Amgen , DAIICHI SANKYO COMPANY LIMITED, Alnylam Pharmaceuticals , Dr. Reddy's Laboratories , Esperion Therapeutics , Formac Pharmaceuticals N.V..
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
